ACVIM 关于治疗猫狗免疫性血小板减少症的共识声明。

IF 2.1 2区 农林科学 Q1 VETERINARY SCIENCES
Dana N. LeVine, Robert Goggs, Barbara Kohn, Andrew J. Mackin, Linda Kidd, Oliver A. Garden, Marjory B. Brooks, Erin R. B. Eldermire, Anthony Abrams-Ogg, Elizabeth H. Appleman, Todd M. Archer, Domenico Bianco, Shauna L. Blois, Benjamin M. Brainard, Mary Beth Callan, Claire L. Fellman, Jillian M. Haines, Anne S. Hale, Alice A. Huang, John M. Lucy, Shana K. O'Marra, Elizabeth A. Rozanski, John M. Thomason, Jenny E. Walton, Helen E. Wilson
{"title":"ACVIM 关于治疗猫狗免疫性血小板减少症的共识声明。","authors":"Dana N. LeVine,&nbsp;Robert Goggs,&nbsp;Barbara Kohn,&nbsp;Andrew J. Mackin,&nbsp;Linda Kidd,&nbsp;Oliver A. Garden,&nbsp;Marjory B. Brooks,&nbsp;Erin R. B. Eldermire,&nbsp;Anthony Abrams-Ogg,&nbsp;Elizabeth H. Appleman,&nbsp;Todd M. Archer,&nbsp;Domenico Bianco,&nbsp;Shauna L. Blois,&nbsp;Benjamin M. Brainard,&nbsp;Mary Beth Callan,&nbsp;Claire L. Fellman,&nbsp;Jillian M. Haines,&nbsp;Anne S. Hale,&nbsp;Alice A. Huang,&nbsp;John M. Lucy,&nbsp;Shana K. O'Marra,&nbsp;Elizabeth A. Rozanski,&nbsp;John M. Thomason,&nbsp;Jenny E. Walton,&nbsp;Helen E. Wilson","doi":"10.1111/jvim.17079","DOIUrl":null,"url":null,"abstract":"<p>Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence-based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell–containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence-based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.</p>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256181/pdf/","citationCount":"0","resultStr":"{\"title\":\"ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats\",\"authors\":\"Dana N. LeVine,&nbsp;Robert Goggs,&nbsp;Barbara Kohn,&nbsp;Andrew J. Mackin,&nbsp;Linda Kidd,&nbsp;Oliver A. Garden,&nbsp;Marjory B. Brooks,&nbsp;Erin R. B. Eldermire,&nbsp;Anthony Abrams-Ogg,&nbsp;Elizabeth H. Appleman,&nbsp;Todd M. Archer,&nbsp;Domenico Bianco,&nbsp;Shauna L. Blois,&nbsp;Benjamin M. Brainard,&nbsp;Mary Beth Callan,&nbsp;Claire L. Fellman,&nbsp;Jillian M. Haines,&nbsp;Anne S. Hale,&nbsp;Alice A. Huang,&nbsp;John M. Lucy,&nbsp;Shana K. O'Marra,&nbsp;Elizabeth A. Rozanski,&nbsp;John M. Thomason,&nbsp;Jenny E. Walton,&nbsp;Helen E. Wilson\",\"doi\":\"10.1111/jvim.17079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence-based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell–containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence-based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.</p>\",\"PeriodicalId\":49958,\"journal\":{\"name\":\"Journal of Veterinary Internal Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256181/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Internal Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17079\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17079","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

犬猫免疫性血小板减少症(ITP)的治疗在不断发展,但目前还没有循证指南来帮助临床医生做出治疗决定。同样,治疗 ITP 的总体目标也尚未确定。免疫抑制剂量的糖皮质激素是一线治疗方法,但糖皮质激素以外的最佳治疗方案仍不确定。其他选择包括二级免疫抑制剂,如硫唑嘌呤、改良环孢素和霉酚酸酯,通常根据临床医生的偏好选择。长春新碱、人IV免疫球蛋白(hIVIg)和输注血小板或含红细胞的产品通常用于病情较重的病例。脾切除术和血小板生成素受体激动剂通常用于难治性病例,但何时以及对哪些患者使用这些方法仍存在争议。为了制定以证据为基础的ITP患者个体化治疗指南,我们提出了20个人群干预比较结果(PICO)格式的问题。17 位证据评估员利用结构化检索策略确定的 288 篇文献对这些问题进行了讨论。证据评估员使用小组设计的模板和数据提取工具,总结证据并创建指南建议。这些建议由治疗领域主席进行整合,然后通过反复的德尔菲调查审查进行完善,最终就最终指南达成共识。此外,19 个非 PICO 问题涉及缺乏证据或证据质量较低的情况,这些问题通过专家意见,采用德尔菲迭代调查的方式进行回答,并由专家小组成员进行整合和完善。在最终达成共识之前,还征求了多个相关专业组织的意见。通过严格的共识过程,发现对比治疗研究很少,突出了ITP治疗中需要进行更多研究的许多领域。本声明是《ACVIM 犬猫免疫性血小板减少症诊断共识声明》的配套手稿。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats

ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats

Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence-based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell–containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence-based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.50
自引率
11.50%
发文量
243
审稿时长
22 weeks
期刊介绍: The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信